Fifth International Conference on Cancer Research and Drug Development (Virtual)

October 26-28, 2020

Sponsor: UNITED Scientific Group
### Plenary Talk

**09:00-09:45 Title:** Using Networks to Understand Cancer Risk  
*John Quackenbush,* Harvard TH Chan School of Public Health, Channing Division of Network Medicine, and Dana-Farber Cancer Institute, MA, USA

### Immunotherapy in Cancer

**Chair:**  
*Eduardo Davila,* University of Colorado CU Comprehensive Cancer Center, CO

**09:45-10:15 Title:** Oncolytic Reagents may also Enhance Anti-Tumor Immunity by Inducing MyD88-dependent Maturation of Dendritic Cells  
*Joost J. Oppenheim,* NIH/NCI, MD, USA

**10:15-10:45 Title:** Overcoming a Frequent Inborn Immune Defect in Breast Cancer Therapy  
*Guido Kroemer,* Gustave Roussy Comprehensive Cancer Center, INSERM, France

**10:45-11:00 Break**

**11:00-11:30 Title:** Versamune (R-D0TAP): a Transformative Cationic Lipid Nanoparticle Technology Associated with Type I Interferon Specific Activation and Generation of Antibody, CD8 and CD4 T Cell Responses to Recombinant Proteins and Peptide Tumor Antigens  
*Lauren V. Wood,* Chief Medical Officer, PDS Biotechnology, NJ

**11:30-11:55 Title:** A Novel Approach to Engineering Antibody Based Immunotherapy  
*Wayne Godfrey,* Vice President of Clinical Development at IGM Bioscience

**11:55-12:20 Title:** Title to be updated  
*Scott K. Durum,* NCI/CCR, NIH, MD, USA

**12:20-12:45 Title:** Novel Gene Platforms to Maintain the Persistence and Antitumor Activity of TIL-, CAR-, and DC-Based Therapies  
*Eduardo Davila,* University of Colorado CU Comprehensive Cancer Center, CO

**12:45-13:10 Lunch**

**13:10-13:35 Title:** UNITE Platform, A Direct Antigen Presentation Approach in Oncology  
*William Heart,* Ph.D. CEO, Immunomic Therapeutics, MD

**13:35-14:00 Title:** Dual Antagonism of Prostaglandin Receptors EP2 and EP4 by TPST-1495 Suppresses Tumor Growth and Stimulates Antitumor Immunity  
*Brian Francica,* Tempest Therapeutics, CA

**14:00-14:25 Title:** MHC Class-I Independent Activation of Virtual-Memory CD8 T Cells Induced by Chemotherapeutic Agent-Treated Cancer Cells  
*Jing H. Wang,* University of Colorado Anschutz Medical Campus, CO

**14:25-14:35 Break**
14:35-15:00  Title: The MAPK/ERK-regulated MEF-2 isoforms as potential new target(s) for HTLV-1 induced Adult T-cell leukemia/lymphoma (ATLL)
Pooja Jain, Drexel University College of Medicine, Philadelphia, PA

15:00-15:25  Title: Performance Optimization of a Novel HPV VLP Vaccine in Mice with Novel Adjuvants
Jason D. Marshall, Leidos Biomedical Research, Inc., NCI Campus at Frederick, MD

15:25-15:50  Title: Duality of NO in Melanoma
Joseph Markowitz, Moffit Cancer Center, FL

15:50-16:15 Title: Finetune Your CARs: Building the Next Generation of Anti-Cancer Therapies
Yan Leyfman, Penn State College of Medicine, PA

E - POSTERS

E-P01  Title: Evaluating The Correlation Between Aspirin Consumption And The Risk Of Developing Actinic Keratosis
Maximiliano Guerra, Holy Cross Hospital, Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, USA

E-P02  Title: Evaluating The Risk Of Thiazides And ACE Inhibitors Exposure And Cutaneous Malignant Neoplasm
Jason Shao, Holy Cross Hospital, Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, USA

E-P03  Title: Evaluating The Correlation Between Folic Acid Exposure And The Risk Of Developing Actinic Keratosis
Ana Gabriela Santizo Orellana, Holy Cross Hospital, Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, USA

E-P04  Title: Evaluating the Risk of Thiazide and Angiotensin Converting Enzyme Inhibitors Exposure and Squamous Cell Carcinoma Development
Amalia Ardeljan, Holy Cross Hospital, Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, USA

Concluding Remarks for the day
**08:30-09:00**  
**Zoom Meeting Joining and Welcome**

**Session:** New Concepts and Potential Chemotherapy for Treatment & Prevention of Cancers Symposium

**Chairs:**  
Leslie C. Costello, University of Maryland, Greenebaum Comprehensive Cancer Center, MD  
Renty B. Franklin, University of Maryland School of Dentistry, MD

**09:00-09:25**  
**Title:** To be Updated  
Vincent C. O. Njar, Marlene and Stewart Greenebaum Comprehensive Cancer Center; University of Maryland School of Medicine, MD

**09:25-09:50**  
**Title:** Therapeutic Potential of Antidiabetic Biguanides in Oral Oncology  
Abraham Schneider, University of Maryland School of Dentistry Greenebaum Comprehensive Cancer Center, MD

**09:50-10:15**  
**Title:** Transcriptional Characterization of de novo Chemo-Refractory Acute Myeloid Leukemia  
Sachi Horibata, NCI/NIH, MD

**10:15-10:30**  
**Break**

**10:30-11:10**  
**Title:** To be Updated  
Leslie C. Costello, University of Maryland, Greenebaum Comprehensive Cancer Center, MD

**11:10-11:40**  
**Title:** The Role of Cellular Metabolism in the Pathogenesis of Prostate Cancer  
Renty B. Franklin, University of Maryland School of Dentistry, MD

**11:40-11:50**  
**Concluding Remarks**

**12:00-12:30**  
**Lunch Break**

**Industry Symposium**  
Transport and Metabolism in Drug Development

**Chairs:**  
Yan Zhang, Director, Nuvation Bio, NY  
Jason Boer, Director, Incyte Corporation, DE

**12:40-13:10**  
**Title:** Interplay of Transporters and Drug-Metabolizing Enzymes in Drug Disposition and Interaction: Scientific and Industry Perspectives  
Hong Shen, Bristol Myers Squibb, NJ

**13:10-13:40**  
**Title:** Title to be updated  
Xinning Yang, CDER, FDA

**13:40-14:10**  
**Title:** Title to be updated  
Kenneth R. Brouwer, Vice President, Technology - ADME-TOX, BioIVT

**14:10-14:40**  
**Title:** Novel in vitro Human Hepatic and Enteric Systems for the Evaluation of Drug Uptake, Metabolism, and Toxicity  
Albert Li, In Vitro ADMET Laboratories Inc., Columbia, MD and Malden, MA
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker, Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:40-14:50</td>
<td><strong>Break</strong></td>
<td></td>
</tr>
<tr>
<td>14:50-15:20</td>
<td><strong>Title:</strong> Atypical Metabolic Pathways and Associated DDI/Toxicity</td>
<td>Jason Boer, Director, Incyte Corporation, DE</td>
</tr>
<tr>
<td>15:20-15:50</td>
<td><strong>Title:</strong> Metabolism and DDI/Tox in Cancer Drug Development</td>
<td>Cyrus Khojasteh</td>
</tr>
<tr>
<td>15:50-16:20</td>
<td><strong>Title:</strong> Metabolism Based Drug Interactions: Impact on Co-dosing</td>
<td>Michael Mohutsky</td>
</tr>
</tbody>
</table>

**E - POSTERS**

**E-P01**  
**Title:** Evaluation of the Correlation Between Angiotensin Receptor Blocker and Risk of Actinic Keratosis  
Divesh Manjani, Holy Cross Hospital, Michael and Dianne Bienes Comprehensive cancer center, Fort Lauderdale, Florida, USA

**E-P02**  
**Title:** An Evaluation Of The Correlation Between Aspirin Consumption And Basal Cell Carcinoma Development  
Lexi Frankel, Holy Cross Hospital, Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, USA

**E-P03**  
**Title:** Examining The Correlation Between Folic Acid Exposure And The Risk Of Developing Basal Cell Carcinoma  
Kishan Shingala, Holy Cross Hospital, Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, USA

**E-P04**  
**Title:** Evaluating The Correlation Between Angiotensin Converting Inhibitor Exposure And Development Of Basal Cell Carcinoma  
Stephanie Shimon, Holy Cross Hospital, Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, Florida, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30-09:00</td>
<td>Zoom Meeting Joining and Welcome</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00-09:30</td>
<td>Plenary Talk</td>
<td><strong>Title:</strong> Metabolic Reprogramming in Cancer: The Bridge that Connects Intracellular pH Stress and Cancer Behaviors</td>
<td>Ying Xu, The University of Georgia, GA</td>
</tr>
<tr>
<td></td>
<td><strong>Session:</strong> Discussions on Cancer Metabolism, Metastasis and Targeted Therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30-09:35</td>
<td>Welcome of Chairs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chairs:</td>
<td>William P. Schiemann, Case Comprehensive Cancer Center, Case Western Reserve University, OH</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>William H. Gmeiner, Wake Forest University, NC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:35-10:00</td>
<td>Title: Development of Two Monoclonal Antibodies Targeting the Interleukin-7 Receptor for Leukemia Treatment</td>
<td>Scott T.R. Walsh, CCR/NCI/NIH, MD</td>
<td></td>
</tr>
<tr>
<td>10:00-10:25</td>
<td>Title: Improved Efficacy and Reduced Systemic Toxicity of the Polymeric Fluoropyrimidine CF10 in Pre-Clinical Models of Colorectal Cancer</td>
<td>William H. Gmeiner, Wake Forest University, NC</td>
<td></td>
</tr>
<tr>
<td>10:25-10:35</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:35-11:00</td>
<td>Title: Acquired Deficiency of the Peroxisomal Enzyme Enoyl-CoA Hydratase/3-Hydroxyacyl CoA Dehydrogenase (Ehhadh) is a Metabolic Vulnerability in a Mouse Model of Hepatoblastoma</td>
<td>Edward V. Prochownik, UPMC Children’s Hospital of Pittsburgh, PA</td>
<td></td>
</tr>
<tr>
<td>11:00-11:25</td>
<td>Title: SLX4IP and Telomere Dynamics Dictate Breast Cancer Metastasis and Therapy Response</td>
<td>William P. Schiemann, Case Comprehensive Cancer Center, Case Western Reserve University, OH</td>
<td></td>
</tr>
<tr>
<td>11:25-11:50</td>
<td>Title: Enhancing Chemotherapeutic Efficacy in Colon Cancer through Serine Deprivation</td>
<td>David C. Montrose, Stony Brook University, NY</td>
<td></td>
</tr>
<tr>
<td>11:50-12:10</td>
<td>Title: Hyaluronic acid receptor-RHAMM mediates Renal Carcinoma Metastasis</td>
<td>Heriberto Moran, The City College of The City University of New York, New York, NY</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Plenary Talk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:10-12:45</td>
<td>Title: Identification of Novel Epigenetic Targets in Thoracic Malignancies Using Induced Pluripotent Stem Cell Models</td>
<td>David S. Schrump, National Cancer Institute, MD</td>
<td></td>
</tr>
<tr>
<td>12:45-13:15</td>
<td>Lunch</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Session: Breast Cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:15-13:20</td>
<td>Welcome of Chairs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chairs:</td>
<td>Yan Peng, UT Southwestern Medical Center Dallas, TX USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Xingyi Guo, Vanderbilt University Medical Center, TN</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:20-14:00</td>
<td>Title: MLN4924 Inhibits Growth and Enhances Cisplatin-Induced Cytotoxicity of Triple Negative Breast Cancer by Inhibiting Nucleotide Excision Repair Pathway</td>
<td>Alo Ray, The Ohio State University, Columbus, OH</td>
<td></td>
</tr>
</tbody>
</table>

Session: Discussions on Cancer Metabolism, Metastasis and Targeted Therapy

**Session:** Breast Cancer

**Welcome of Chairs**

**Chairs:**

Yan Peng, UT Southwestern Medical Center Dallas, TX USA

Xingyi Guo, Vanderbilt University Medical Center, TN

**Title:** MLN4924 Inhibits Growth and Enhances Cisplatin-Induced Cytotoxicity of Triple Negative Breast Cancer by Inhibiting Nucleotide Excision Repair Pathway

**Speaker:** Alo Ray, The Ohio State University, Columbus, OH
<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-14:20</td>
<td><strong>Title: Breast Cancer Tumor Biomarkers: Issues in Clinical Practice</strong></td>
<td>Yan Peng, UT Southwestern Medical Center Dallas, TX USA</td>
<td></td>
</tr>
<tr>
<td>14:20-14:40</td>
<td><strong>Title: Discovery of Susceptibility Gene in Breast Cancer</strong></td>
<td>Xingyi Guo, Vanderbilt University Medical Center, TN</td>
<td></td>
</tr>
<tr>
<td>14:40-15:00</td>
<td><strong>Title: Metabolically Targeting Epithelial-Mesenchymal Plasticity of Breast Cancer Stem Cells</strong></td>
<td>Ming Luo, University of Michigan, MI</td>
<td></td>
</tr>
<tr>
<td>15:00-15:10</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Session:</strong> Novel Therapeutic Targets in Cancer; Cancer Drug Development</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Heredity and Cancer Genomics; Tumor Microenvironment</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:10-15:15</td>
<td><strong>Welcome of Chairs</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:15-15:40</td>
<td><strong>Title: Long-Read Sequencing of Human Transcription</strong></td>
<td>Jianhua Luo, University of Pittsburgh Medical Center, PA</td>
<td></td>
</tr>
<tr>
<td>15:40-16:00</td>
<td><strong>Title: The Thomsen Friedenreich Tumor-Associated Carbohydrate Antigen in Anticancer Nanoparticle Drug Discovery</strong></td>
<td>Joseph J. Barchi Jr, NIH/NCI, MD</td>
<td></td>
</tr>
<tr>
<td>16:00-16:20</td>
<td><strong>Title: Light-Sensitive Cancer Nanomedicine for On-Demand Delivery of Anti-cancer Agents and RNAi Therapeutics</strong></td>
<td>Anu Puri, National Cancer Institute-Frederick, National Institutes of Health, Frederick, MD</td>
<td></td>
</tr>
<tr>
<td>16:20-16:30</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30-16:50</td>
<td><strong>Title: Anthracycline-Induced Conformational Changes of P-glycoprotein during Transport</strong></td>
<td>Arthur G Roberts, The University of Georgia College of Pharmacy, GA</td>
<td></td>
</tr>
<tr>
<td>16:50-17:10</td>
<td><strong>Title: Interleukin-17 in Colorectal Cancer and Immunity</strong></td>
<td>Kepeng Wang, Department of Immunology, UConn Health, CT</td>
<td></td>
</tr>
<tr>
<td>17:10-17:30</td>
<td><strong>Title: Hypoxia Suppresses Lysosomal Activity and Receptor Tyrosine Kinase Degradation</strong></td>
<td>Jaewoo Hong, CCR/NCI/NIH, MD</td>
<td></td>
</tr>
</tbody>
</table>

**Contact:**

**Kinnera Kalagara**  
Conference Manager-Cancer R&D 2020  
**Email:** kkalagara@uniscigroup.net

**For Organizing Committee**

USG United Scientific Group (A non-profit organization)

# 8105, Suite 112, Rasor Blvd, PLANO, TX 75024

**Tel:** +1 469-854-2281  
**Web:** https://cancer.unitedscientificgroup.org/  
**LinkedIn:** https://www.linkedin.com/in/kinnera-kalagara-612600118/  
**Twitter:** @KK_usgcancer